Global Exosomes Pipeline Insight Report 2020: Insights on 50+ Companies and 50+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Exosomes – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The Exosomes – Pipeline Insight, 2020 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the rapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Exosomes Emerging Drugs Chapters

This segment of the Exosomes report encloses its detailed analysis of various drugs in the different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Exosomes Emerging Drugs

Neural exosomes (AB126): ArunA Biomedical

ArunA Biomedical’s proprietary neural exosomes cross the blood-brain barrier inherently and enable drugs and drug-combinations to naturally target cells and treat patients with a range of neurological disorders. Preclinical studies have demonstrated the rapeutic potential of these exosomes in multiple stroke models. These studies have shown that the exosomes enhance the nervous system’s self-repair mechanisms, translating into structural and functional benefits which may have improved survival, reduced infarct size, and improved mobility.

ExoPr0: ReNeuron

The company’s CTX-derived exosomes candidate is currently in the preclinical stage and is being developed as a novel vector for delivering the third party biological drugs. (Read more…) ExoPr0 has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle in established preclinical disease models. The company intends to devote more significant resources to the application of ExoPr0 as a vector for delivering drugs.

exoIL-12: Codiak Biosciences

exoIL-12 is a precision-engineered exosome therapeutic candidate expressing IL-12 on the surface of the exosome by molecular fusion to Codiak’s proprietary scaffold protein, PTGRFN. Developed via Codiak’s proprietary engEx platform, exoIL-12 is designed to target T-cells and Natural Killer cells and induce systemic anti-tumor immunity. Data from Codiak’s preclinical studies suggest that when administered intratumorally, exoIL-12 is retained in the tumor microenvironment, thus resulting in potent antitumor immunity and an improved toxicity profile compared to recombinant IL-12.

Exosomes: Therapeutic Assessment

This segment of the report provides insights about the different Exosomes based drugs segregated based on the following parameters that define the scope of the report, such as:

Major Players in Exosomes

There are approx. 50+ key companies which are developing the rapies for Exosomes. The companies which have their Exosomes drug candidates in the early stages, i.e. phase I include United Therapeutics Corporation.

This report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase II and Phase II/III)
• Mid-stage products (Phase II and Phase II/III)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Exosomes pipeline report provides the rapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intramuscular
• Intranasal
• Parenteral
• Intravenous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Vaccines
• Polymers
• Peptides
• Enzymes
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Exosomes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Exosomes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exosomes drugs.

Key Players

• Direct Biologics
• Codiak BioSciences
• ExoCyte Therapeutics
• Avalon GloboCare
• United Therapeutics Corporation
• Capricor Therapeutics
• Avalon GloboCare
• Azymus Therapeutics
• Versatope Therapeutics
• Lamellar Biomedical
• Celltrion

Key Products

• LAMELLASOME IPF-NA
• exoSTING
• ET-08
• AVA 201
• Unexisome
• CAP 2003
• exoIL 12
• AVA 203
• AZ 001
• VT 105

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/4d56xk

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900